A healthcare worker administers doses of the AstraZeneca Covid-19 vaccine at a vaccine hub in Rome in June 2021. Despite its widespread popularity and success, AstraZeneca has announced that it will be withdrawing its highly successful coronavirus vaccine, known as Vaxzevria, due to declining demand. The company has stated that since April 2023, the vaccine has not generated any revenue.
This decision comes after a surge of new Covid-19 vaccines became available on the market, causing a surplus of vaccines and prompting AstraZeneca to cease manufacturing and supplying the product. As a result, the company has initiated the withdrawal of marketing authorizations for Vaxzevria within Europe.
The European Medicines Agency (EMA) has also announced the withdrawal of Vaxzevria’s marketing authorization in EU countries. However, AstraZeneca remains committed to working with regulators in other countries to determine the best course of action for the vaccine’s commercial future.
Despite the discontinuation of Vaxzevria, AstraZeneca is proud of its role in contributing to the global effort to end the pandemic. Over 3 billion doses of Vaxzevria have been supplied worldwide since January 4th, 2021. This is a developing story and updates will be provided as more information becomes available.